Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients
- 06.11.2019
- Original Article – Clinical Oncology
Erschienen in:
- Verfasst von
- Vincenzo Catalano
- Francesca Bergamo
- Chiara Cremolini
- Bruno Vincenzi
- Francesca Negri
- Paolo Giordani
- Paolo Alessandroni
- Rossana Intini
- Silvia Stragliotto
- Daniele Rossini
- Beatrice Borelli
- Daniele Santini
- Donatella Sarti
- Marco B. L. Rocchi
- Sara Lonardi
- Alfredo Falcone
- Vittorina Zagonel
- Rodolfo Mattioli
- Francesco Graziano
- Erschienen in
- Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2020
Abstract
Purpose
In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We investigated whether bevacizumab combined with different chemotherapy regimens may have an impact on clinical outcomes of MCRC patients with mucinous histology.
Methods
685 MCRC patients were classified in mucinous adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC) and were treated with first-line bevacizumab plus fluoropyrimidine (FP)-based, oxaliplatin (OXA)-based, irinotecan (IRI)-based, or FOLFOXIRI.
Results
Ninety-four (13.7%) patients had MC. With a median follow-up of 50 months, MC patients had a median overall survival (OS) of 28.2 months compared with 27.7 months for the NMC group [hazard ratio (HR) = 0.92; 95% confidence interval (CI) 0.70–1.19, P = 0.530]. The overall response rates for MC and NMC were 41.5% (95% CI 31.5–51.4) and 62.4% (95% CI 58.4–66.3), respectively (Chi-square test, P <0.003). After correcting for significant prognostic factors by multivariate Cox regression analysis, age, resection of the primary tumour, and number of metastatic sites were found to be associated with poorer OS, but not mucinous histology.
Conclusion
Compared with NMC, MCRC patients with mucinous histology treated with bevacizumab plus chemotherapy had comparable OS despite lower overall response rate.
Anzeige
- Titel
- Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients
- Verfasst von
-
Vincenzo Catalano
Francesca Bergamo
Chiara Cremolini
Bruno Vincenzi
Francesca Negri
Paolo Giordani
Paolo Alessandroni
Rossana Intini
Silvia Stragliotto
Daniele Rossini
Beatrice Borelli
Daniele Santini
Donatella Sarti
Marco B. L. Rocchi
Sara Lonardi
Alfredo Falcone
Vittorina Zagonel
Rodolfo Mattioli
Francesco Graziano
- Publikationsdatum
- 06.11.2019
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335 - DOI
- https://doi.org/10.1007/s00432-019-03077-w
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
